
Eli Lilly & Co. (LLY), Novartis AG (NVS), and Wyeth (WYE) joined Pfizer with gains driven by price increases and growth in new prescriptions. The change was most noticeable at Lilly with United States prices rising 11 percent.
Pfizer, along with other drug makers such as Merck & Co. Inc. (MRK) were facing flat revenues, with Pfizer facing key drug patents expiring in 2008, but profits instead rose sharply after a decade of weakness.
Know More about pharmaceuticals at ThePharmVoice.com.






Comment Preview